|
US5234814A
(en)
*
|
1989-06-01 |
1993-08-10 |
Du Pont Merck Pharmaceutical Company |
Diagnostic assay for alzheimer's disease
|
|
US6693076B1
(en)
|
1989-06-05 |
2004-02-17 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factors and analogs
|
|
US5652214A
(en)
*
|
1989-06-05 |
1997-07-29 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factors and analogs
|
|
US5093317A
(en)
*
|
1989-06-05 |
1992-03-03 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factor
|
|
US6723699B1
(en)
|
1989-06-05 |
2004-04-20 |
Cephalon, Inc. |
Treating disorders by application of insulin-like growth factors and analogs
|
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
|
US5624898A
(en)
|
1989-12-05 |
1997-04-29 |
Ramsey Foundation |
Method for administering neurologic agents to the brain
|
|
CA2070823C
(en)
*
|
1989-12-05 |
1999-01-12 |
William H. Ii Frey |
Neurologic agents for nasal administration to the brain
|
|
US6407061B1
(en)
|
1989-12-05 |
2002-06-18 |
Chiron Corporation |
Method for administering insulin-like growth factor to the brain
|
|
US5130129A
(en)
*
|
1990-03-06 |
1992-07-14 |
The Regents Of The University Of California |
Method for enhancing antibody transport through capillary barriers
|
|
AU1991592A
(en)
|
1991-04-30 |
1992-12-21 |
Alkermes, Inc. |
Cationized antibodies against intracellular proteins
|
|
JP2930421B2
(ja)
*
|
1994-02-28 |
1999-08-03 |
メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング |
薬剤組成物、その製造方法及びその使用方法
|
|
US5639940A
(en)
|
1994-03-03 |
1997-06-17 |
Pharmaceutical Proteins Ltd. |
Production of fibrinogen in transgenic animals
|
|
US6709653B1
(en)
*
|
1994-09-16 |
2004-03-23 |
Human Genome Sciences, Inc. |
Antibodies specific for human inositol monophosphatase H1
|
|
GB9509620D0
(en)
|
1995-05-12 |
1995-07-05 |
Nat Blood Authority |
Transepithelial transport of molecular species
|
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
|
CA2277519A1
(en)
|
1997-01-10 |
1998-07-16 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in alzheimer's disease by .beta.-amyloid peptides
|
|
US6942963B1
(en)
|
1997-01-10 |
2005-09-13 |
Massachusetts Institute Of Technology |
Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
|
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
|
US20030147882A1
(en)
*
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
|
NZ507727A
(en)
*
|
1998-05-21 |
2003-11-28 |
Univ Tennessee Res Foundation |
Methods for amyloid removal using anti-amloid antibodies
|
|
US7273618B2
(en)
|
1998-12-09 |
2007-09-25 |
Chiron Corporation |
Method for administering agents to the central nervous system
|
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
AUPQ180499A0
(en)
*
|
1999-07-23 |
1999-08-19 |
Biomolecular Research Institute Limited |
Beta-amyloid peptide inhibitors
|
|
CN1426423B
(zh)
*
|
2000-02-24 |
2010-05-12 |
华盛顿大学 |
螯合淀粉样蛋白β肽的人源化抗体
|
|
EP2226385B1
(de)
|
2000-09-13 |
2013-07-10 |
Novo Nordisk Health Care AG |
Varianten des menschlichen Koagulationsfaktors VII
|
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
|
EP1341548A4
(de)
*
|
2000-11-03 |
2006-06-14 |
Massachusetts Inst Technology |
VERFAHREN ZUR IDENTIFIZIERUNG VON BEHANDLUNGEN GEGEN NEUROTOXIZITÄT BEI ALZHEIMER-KRANKHEIT, DIE DURCH $g(b)-AMYLOIDPEPTIDE HERVORGERUFEN WIRD
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
PE20020574A1
(es)
*
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
HUP0401124A3
(en)
|
2001-03-22 |
2006-01-30 |
Novo Nordisk Healthcare Ag |
Coagulation factor vii derivatives
|
|
US20020172676A1
(en)
*
|
2001-05-16 |
2002-11-21 |
George Jackowski |
Method of treatment of alzheimer's disease and device therefor
|
|
US7041314B2
(en)
|
2001-05-24 |
2006-05-09 |
Neuren Pharmaceuticals Ltd. |
GPE analogs and peptidominetics
|
|
US7605177B2
(en)
|
2001-05-24 |
2009-10-20 |
Neuren Pharmaceuticals Limited |
Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
|
|
US7714020B2
(en)
|
2001-05-24 |
2010-05-11 |
Neuren Pharmaceuticals Limited |
Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
|
|
US20030096748A1
(en)
*
|
2001-06-04 |
2003-05-22 |
The Regents Of The University Of Michigan |
Methods and compositions for the treatment of diseases associated with signal transduction aberrations
|
|
DK1944040T3
(da)
*
|
2001-08-17 |
2012-10-29 |
Univ Washington |
Analysefremgangsmåde for Alzheimers sygdom
|
|
US20030082191A1
(en)
*
|
2001-08-29 |
2003-05-01 |
Poduslo Joseph F. |
Treatment for central nervous system disorders
|
|
MY139983A
(en)
*
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7074893B2
(en)
*
|
2002-06-03 |
2006-07-11 |
Regents Of The University Of Michigan |
Methods and compositions for the treatment of diseases associated with signal transduction aberrations
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
ZA200505782B
(en)
*
|
2003-02-01 |
2006-09-27 |
Neuralab Ltd |
Active immunization to generate antibodies to soluble A-beta
|
|
US7575747B2
(en)
*
|
2003-02-10 |
2009-08-18 |
Applied Molecular Evolution |
Aβ binding molecules
|
|
EP3103869A1
(de)
|
2003-03-18 |
2016-12-14 |
Novo Nordisk Health Care AG |
Verfahren zur herstellung von factor vii polypeptiden
|
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
|
CN101870729A
(zh)
|
2003-09-09 |
2010-10-27 |
诺和诺德医疗保健公司 |
凝固因子ⅶ多肽
|
|
AU2004293471C1
(en)
|
2003-11-25 |
2011-02-24 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services |
Mutated anti-CD22 antibodies and immunoconjugates
|
|
US20050272722A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
|
JP2007529555A
(ja)
*
|
2004-03-18 |
2007-10-25 |
ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド |
シヌクレイノパチーを治療する方法
|
|
US20060106060A1
(en)
*
|
2004-03-18 |
2006-05-18 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies (Lansbury)
|
|
EP1744751A4
(de)
*
|
2004-03-18 |
2010-03-10 |
Brigham & Womens Hospital |
Verfahren zur behandlung von synucleinopathien
|
|
US20050272068A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
UCH-L1 expression and cancer therapy
|
|
PE20061329A1
(es)
*
|
2004-12-15 |
2006-12-08 |
Neuralab Ltd |
Anticuerpos ab humanizados para mejorar la cognicion
|
|
TW200635608A
(en)
*
|
2004-12-15 |
2006-10-16 |
Neuralab Ltd |
Aβ antibodies for use in improving cognition
|
|
PE20061152A1
(es)
*
|
2004-12-15 |
2006-10-13 |
Neuralab Ltd |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
|
EP3050963B1
(de)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur herstellung von polypeptiden durch regulierung der anordnung
|
|
CU23317A1
(es)
|
2005-07-22 |
2008-10-22 |
Ct De Investigacia N Y Desarro |
Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
|
|
PL3006458T3
(pl)
|
2005-07-29 |
2018-05-30 |
The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services |
Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości
|
|
CA2618306C
(en)
|
2005-08-08 |
2014-10-21 |
Oregon Health & Science University |
Inactivating pathogens with hydrogen peroxide for vaccine production
|
|
US8507439B2
(en)
|
2005-08-29 |
2013-08-13 |
Angela Shashoua |
Neuroprotective and neurorestorative method and compositions
|
|
US20100130425A1
(en)
|
2005-09-09 |
2010-05-27 |
Oregon Health & Science University |
Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
|
|
EP1926817A2
(de)
|
2005-09-14 |
2008-06-04 |
Novo Nordisk Health Care AG |
Menschliche gerinnungsfaktor-vii-polypeptide
|
|
CN102898519B
(zh)
|
2005-11-30 |
2015-10-28 |
Abbvie公司 |
抗淀粉样β蛋白的单克隆抗体及其用途
|
|
EP2289909B1
(de)
|
2005-11-30 |
2014-10-29 |
AbbVie Inc. |
Screeningsverfahren, Verfahren zur Reinigung von nicht-diffundierenden Beta-Oligomeren, selektive Antikörper gegen genannten nichtdiffundierende Beta-Oligomere und Verfahren zur Herstellung von genannten Antikörpern
|
|
CA2633887C
(en)
|
2005-12-15 |
2015-12-22 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
|
JP2009521470A
(ja)
|
2005-12-23 |
2009-06-04 |
リンク メディシン コーポレイション |
シヌクレイン障害の治療
|
|
EP2397856B1
(de)
|
2006-03-14 |
2013-11-13 |
Oregon Health and Science University |
Methoden zur Detektion einer Mycobakterium tuberculosis Infektion
|
|
CN105177091A
(zh)
|
2006-03-31 |
2015-12-23 |
中外制药株式会社 |
用于纯化双特异性抗体的抗体修饰方法
|
|
WO2007114319A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
抗体の血中動態を制御する方法
|
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
US20100150928A1
(en)
|
2006-05-04 |
2010-06-17 |
Geneetech, Inc. |
Methods and compositions relating to zpa polypeptides
|
|
EP2046833B9
(de)
|
2006-07-14 |
2014-02-19 |
AC Immune S.A. |
Humanisierter antikörper gegen amyloid beta
|
|
TR201802814T4
(tr)
|
2006-07-14 |
2018-03-21 |
Ac Immune Sa |
Amiloid betaya karşı insanlaştırılmış antikor.
|
|
EP3424950A1
(de)
|
2006-10-06 |
2019-01-09 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Prävention von gewebeischämie, damit in zusammenhang stehende verfahren und zusammensetzungen
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
EP2842967B1
(de)
*
|
2007-01-18 |
2016-11-30 |
Eli Lilly and Company |
Pegyliertes Amyloid-beta-Fab
|
|
US20080200441A1
(en)
*
|
2007-02-14 |
2008-08-21 |
University Of Southern California |
Estrogen receptor modulators associated pharmaceutical compositions and methods of use
|
|
EP2124952A2
(de)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Verfahren zur behandlung von amyloidosen
|
|
US8188214B2
(en)
|
2007-02-28 |
2012-05-29 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Brachyury polypeptides and methods for use
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
US20090004213A1
(en)
|
2007-03-26 |
2009-01-01 |
Immatics Biotechnologies Gmbh |
Combination therapy using active immunotherapy
|
|
MX2009011127A
(es)
*
|
2007-04-18 |
2010-03-10 |
Janssen Alzheimer Immunotherap |
Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
|
|
US8003097B2
(en)
*
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
JP2010526636A
(ja)
*
|
2007-05-16 |
2010-08-05 |
イェダ リサーチ アンド デベロップメント カンパニー リミテッド |
血液脳関門破壊の評価
|
|
CL2008001741A1
(es)
|
2007-06-12 |
2008-11-21 |
Genentech Inc |
Anticuerpo quimerico o humanizado o fragmento de los mismos que se unen especificamente a por lo menos un epitope en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados con la formacion de placas amiloides.
|
|
RU2571856C2
(ru)
|
2007-06-12 |
2015-12-20 |
Ац Иммуне С.А. |
Моноклональное тело против амилоида бета
|
|
EP2008666A1
(de)
|
2007-06-29 |
2008-12-31 |
Institut Pasteur |
Verwendung von VHH-Antikörpern zur Herstellung von Peptidvektoren zur Verabreichung einer relevanten Substanz und Anwendungen der Peptidvektoren
|
|
SI2182983T1
(sl)
|
2007-07-27 |
2014-09-30 |
Janssen Alzheimer Immunotherapy |
Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
|
|
PT2197903E
(pt)
|
2007-09-04 |
2015-01-02 |
Us Gov Health & Human Serv |
Delecções no domínio ii da exotoxina a de pseudomonas que reduzem toxicidade não específica
|
|
EP2202245B1
(de)
|
2007-09-26 |
2016-08-24 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zum modifizieren des isoelektrischen punkts eines antikörpers durch aminosäuresubstitution in der cdr
|
|
EP3789400A1
(de)
|
2007-09-26 |
2021-03-10 |
Chugai Seiyaku Kabushiki Kaisha |
Modifizierte antikörperkonstantregion
|
|
SG178809A1
(en)
|
2007-10-05 |
2012-03-29 |
Genentech Inc |
Use of anti-amyloid beta antibody in ocular diseases
|
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-ｖｅｇｆ抗體
|
|
CN101514335B
(zh)
|
2008-02-22 |
2013-04-17 |
中国科学院生物物理研究所 |
流感病毒聚合酶亚基pa的表达纯化及pa氨基端及pa羧基端与pb1氨基端多肽复合体的晶体结构
|
|
US8232402B2
(en)
*
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
|
EP2143735A1
(de)
*
|
2008-07-10 |
2010-01-13 |
Institut Pasteur |
Variable Domänen von Schwerketten-Antikörpern, die sich gegen GFAPs richten
|
|
ES2442024T3
(es)
|
2008-07-15 |
2014-02-07 |
Academia Sinica |
Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
JP5913980B2
(ja)
|
2008-10-14 |
2016-05-11 |
ジェネンテック， インコーポレイテッド |
免疫グロブリン変異体及びその用途
|
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
|
WO2010048446A2
(en)
|
2008-10-22 |
2010-04-29 |
Genentech, Inc. |
Modulation of axon degeneration
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
|
MX2011005096A
(es)
*
|
2008-11-13 |
2011-11-18 |
Link Medicine Corp |
Derivados de azaquinolinona y usos de los mismos.
|
|
US10167263B2
(en)
|
2008-11-20 |
2019-01-01 |
Northwestern University |
Treatment of amyotrophic lateral sclerosis
|
|
EP3318573A1
(de)
|
2008-12-23 |
2018-05-09 |
F. Hoffmann-La Roche AG |
Immunglobulinvarianten mit veränderter bindung an protein a
|
|
US20100189800A1
(en)
*
|
2009-01-23 |
2010-07-29 |
Peter Markland |
Continous double emulsion process for making microparticles
|
|
CN101792745B
(zh)
|
2009-02-04 |
2014-09-17 |
中国科学院生物物理研究所 |
流感病毒聚合酶亚基pa氨基端多肽的表达纯化及pa氨基端多肽的晶体结构
|
|
US8664183B2
(en)
|
2009-02-27 |
2014-03-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
SPANX-B polypeptides and their use
|
|
JP5883653B2
(ja)
*
|
2009-03-10 |
2016-03-15 |
ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ |
抗原提示細胞ターゲティング抗ウイルスワクチン
|
|
CN108373509A
(zh)
*
|
2009-03-10 |
2018-08-07 |
贝勒研究院 |
靶向抗原呈递细胞的抗病毒疫苗
|
|
CN102448989B
(zh)
|
2009-03-10 |
2015-09-30 |
贝勒研究院 |
抗-cd40抗体及其用途
|
|
JP5787446B2
(ja)
|
2009-03-19 |
2015-09-30 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
EP2427438B1
(de)
|
2009-05-05 |
2016-10-12 |
Cambria Pharmaceuticals, Inc. |
Pyrimidin-2,4,6-trione für die behandlung von amyotropher lateralsklerose
|
|
JP2012529432A
(ja)
|
2009-06-05 |
2012-11-22 |
リンク・メディスン・コーポレーション |
アミノピロリジノン誘導体及びその使用
|
|
AU2010272483B2
(en)
|
2009-07-17 |
2016-07-21 |
Omeros Corporation |
MASP isoforms as inhibitors of complement activation
|
|
JP2013502263A
(ja)
|
2009-08-18 |
2013-01-24 |
ベン‐グリオン ユニバーシティ オブ ザ ネゲヴ リサーチ アンド デベロップメント オーソリティ |
撮像データを解析するためのシステムおよび方法
|
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
|
CA2772715C
(en)
|
2009-09-02 |
2019-03-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
CN102655882B
(zh)
|
2009-09-11 |
2014-11-19 |
美国政府健康及人类服务部 |
具有降低的免疫原性的改进的假单胞菌外毒素a
|
|
WO2011038290A2
(en)
|
2009-09-25 |
2011-03-31 |
The U. S. A., As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 and their use
|
|
WO2011047340A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
|
CN104043126A
(zh)
|
2009-10-22 |
2014-09-17 |
霍夫曼-拉罗奇有限公司 |
轴突变性的调节
|
|
WO2011063283A2
(en)
|
2009-11-20 |
2011-05-26 |
Oregon Health & Science University |
Methods for detecting a mycobacterium tuberculosis infection
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
TWI505836B
(zh)
|
2009-12-11 |
2015-11-01 |
Genentech Inc |
抗－ｖｅｇｆ－ｃ抗體及其使用方法
|
|
HUE027713T2
(en)
|
2009-12-23 |
2016-10-28 |
Hoffmann La Roche |
Anti-BV8 antibodies and their use
|
|
WO2011100455A1
(en)
|
2010-02-12 |
2011-08-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Inhibition of antibody responses to foreign proteins
|
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
AU2011222883B2
(en)
|
2010-03-05 |
2016-05-26 |
Omeros Corporation |
Chimeric inhibitor molecules of complement activation
|
|
WO2011112599A2
(en)
|
2010-03-12 |
2011-09-15 |
The United States Of America, As Represented By The Secretary. Department Of Health & Human Services |
Immunogenic pote peptides and methods of use
|
|
AU2011230619C1
(en)
|
2010-03-25 |
2016-06-23 |
Oregon Health & Science University |
CMV glycoproteins and recombinant vectors
|
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
CN102933601B
(zh)
|
2010-04-15 |
2016-06-08 |
Abbvie公司 |
β淀粉样蛋白结合蛋白
|
|
DK2568976T3
(en)
|
2010-05-10 |
2016-01-11 |
Academia Sinica |
Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
|
|
CN104689314B
(zh)
|
2010-06-16 |
2018-02-02 |
高等教育联邦系统-匹兹堡大学 |
内质蛋白的抗体及其用途
|
|
MX341369B
(es)
|
2010-07-30 |
2016-08-17 |
Genentech Inc * |
Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
|
|
EP2603233A1
(de)
|
2010-08-12 |
2013-06-19 |
AC Immune S.A. |
Manipulation von impfstoffen
|
|
US9062101B2
(en)
|
2010-08-14 |
2015-06-23 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
|
JP5974012B2
(ja)
|
2010-10-05 |
2016-08-23 |
ジェネンテック， インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
|
DK2625198T3
(en)
|
2010-10-07 |
2015-09-28 |
Ac Immune Sa |
Antibodies that recognize the phosphorylated tau
|
|
TW201223561A
(en)
|
2010-10-26 |
2012-06-16 |
Ac Immune Sa |
Preparation of an antigenic construct
|
|
TWI452135B
(zh)
|
2010-11-17 |
2014-09-11 |
中外製藥股份有限公司 |
A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
|
|
MX352889B
(es)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo de fc especifico para fcyriib.
|
|
CA2831294A1
(en)
|
2011-03-25 |
2012-10-04 |
Baylor Research Institute |
Compositions and methods to immunize against hepatitis c virus
|
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
|
CN105968209B
(zh)
|
2011-04-19 |
2021-08-03 |
美国政府(由卫生和人类服务部的部长所代表) |
对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
|
|
SG194787A1
(en)
|
2011-05-06 |
2013-12-30 |
Us Gov Health & Human Serv |
Recombinant immunotoxin targeting mesothelin
|
|
LT2691530T
(lt)
|
2011-06-10 |
2018-08-10 |
Oregon Health & Science University |
Cmv glikoproteinai ir rekombinantiniai vektoriai
|
|
US9845327B2
(en)
|
2011-06-22 |
2017-12-19 |
The General Hospital Corporation |
Treatment of proteinopathies
|
|
AU2012284122B2
(en)
|
2011-07-18 |
2017-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods and compositions for inhibiting polyomavirus-associated pathology
|
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
|
WO2013039792A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunogens based on an hiv-1 gp120 v1v2 epitope
|
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
EP3939996A1
(de)
|
2011-09-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
|
|
AU2011378675B2
(en)
|
2011-10-04 |
2017-10-05 |
Epsilogen Ltd |
IgE anti -HMW-MAA antibody
|
|
ES2600915T3
(es)
|
2011-10-07 |
2017-02-13 |
Ac Immune S.A. |
Anticuerpos fosfoespecíficos que reconocen Tau
|
|
EP2768386B1
(de)
|
2011-10-19 |
2024-04-03 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Magnetresonanzkarten zur analyse von gewebe
|
|
EP2586461A1
(de)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Von einem eingehüllten Virus abgeleitete Virenpartikel
|
|
AU2013217986B2
(en)
|
2012-02-09 |
2017-04-27 |
Var2 Pharmaceuticals Aps |
Targeting of chondroitin sulfate glycans
|
|
EP2831277A4
(de)
|
2012-03-29 |
2016-06-29 |
Univ Colorado |
Klick-nucleinsäuren
|
|
CA2869438C
(en)
|
2012-04-05 |
2021-08-17 |
Ac Immune S.A. |
Humanized tau antibody
|
|
WO2013152352A1
(en)
|
2012-04-06 |
2013-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Live, attenuated rubella vector to express vaccine antigens
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
JP6267193B2
(ja)
|
2012-05-22 |
2018-01-24 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
置換ジピリジルアミン類及びそれらの使用
|
|
MX2014014234A
(es)
|
2012-05-22 |
2015-05-07 |
Genentech Inc |
Benzamidas n-sustituidas y su uso en el tratamiento del dolor.
|
|
SG11201407972RA
(en)
|
2012-06-01 |
2015-01-29 |
Us Health |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
|
CA2878478A1
(en)
|
2012-07-06 |
2014-01-09 |
Genentech, Inc. |
N-substituted benzamides and methods of use thereof
|
|
US9914956B2
(en)
|
2012-08-18 |
2018-03-13 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
|
EP2888282B1
(de)
|
2012-08-21 |
2018-03-14 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Domänenspezifische monoklonale mesothelin-antikörper und verwendung davon
|
|
WO2014031762A1
(en)
|
2012-08-21 |
2014-02-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
|
US20150224181A1
(en)
|
2012-09-14 |
2015-08-13 |
The United States Of America As Represented By The Secretary Department Of Health And Human Se |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
|
CN104955845B
(zh)
|
2012-09-27 |
2018-11-16 |
美国政府(由卫生和人类服务部的部长所代表) |
间皮素抗体和引起有效的抗肿瘤活性的方法
|
|
CN104684899B
(zh)
|
2012-09-27 |
2017-07-04 |
霍夫曼-拉罗奇有限公司 |
取代的磺酰胺化合物
|
|
US20150307865A1
(en)
|
2012-10-15 |
2015-10-29 |
Novo Nordisk Health Care Ag |
Coagulation factor vii polypeptides
|
|
WO2014062778A1
(en)
|
2012-10-19 |
2014-04-24 |
Bavarian Nordic, Inc. |
Methods and compositions for the treatment of cancer
|
|
US9775895B2
(en)
|
2012-12-12 |
2017-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HIV therapeutics and methods of making and using same
|
|
KR102390445B1
(ko)
|
2012-12-26 |
2022-04-25 |
온코시너지, 인코포레이티드 |
항-인테그린 β1 항체 조성물 및 이의 이용 방법
|
|
TWI498325B
(zh)
|
2013-01-18 |
2015-09-01 |
Hoffmann La Roche |
３－取代吡唑及其用途
|
|
US9534041B2
(en)
|
2013-02-12 |
2017-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that neutralize a norovirus
|
|
WO2014160183A1
(en)
|
2013-03-13 |
2014-10-02 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Methods for modulating chemotherapeutic cytotoxicity
|
|
US9550775B2
(en)
|
2013-03-14 |
2017-01-24 |
Genentech, Inc. |
Substituted triazolopyridines and methods of use thereof
|
|
CN105143258B
(zh)
|
2013-03-15 |
2020-06-23 |
Ac免疫有限公司 |
抗Tau抗体和使用方法
|
|
WO2014174480A1
(en)
|
2013-04-24 |
2014-10-30 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Magnetic resonance maps for analyzing tissue
|
|
TW201800403A
(zh)
|
2013-05-01 |
2018-01-01 |
赫孚孟拉羅股份公司 |
二雜芳基化合物及其用途
|
|
MX2015014861A
(es)
|
2013-05-01 |
2016-03-09 |
Hoffmann La Roche |
Pirimidinas sustituidas con heterocicloalquilo c-enlazado y sus usos.
|
|
WO2014182532A1
(en)
|
2013-05-07 |
2014-11-13 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Mesothelin-specific immunocytokine and use thereof
|
|
WO2014183052A1
(en)
|
2013-05-09 |
2014-11-13 |
The United States Of America, As Represented By The Secretary, Depart Of Health And Human Services |
Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
|
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
ES2718399T3
(es)
|
2013-07-09 |
2019-07-01 |
Univ Duke |
Moléculas que se acoplan a anticuerpos EGFRVIII biespecíficas humanas
|
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
|
AU2014317889B2
(en)
|
2013-09-06 |
2020-03-05 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
|
US11465978B2
(en)
|
2013-09-11 |
2022-10-11 |
The Administrators Of The Tulane Educational Fund |
Anthranilic amides and the use thereof
|
|
DK3050896T3
(da)
|
2013-09-27 |
2021-07-19 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af en polypeptid-heteromultimer
|
|
EP2873423B1
(de)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
|
JP2016532673A
(ja)
|
2013-10-11 |
2016-10-20 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｔｒｐａ１調節因子として有用な置換複素環式スルホンアミド化合物
|
|
EP3620470B1
(de)
|
2013-10-11 |
2023-07-26 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Tem-8-antikörper und deren verwendung
|
|
WO2015065919A1
(en)
|
2013-10-28 |
2015-05-07 |
The Regents Of The University Of California |
Treatment of metastatic prostate cancer
|
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
|
WO2015095770A1
(en)
|
2013-12-20 |
2015-06-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunogenic jc polyomavirus compositions and methods of use
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
WO2015106003A1
(en)
|
2014-01-08 |
2015-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Ras pathways as markers of protection against hiv and methods to improve vaccine efficacy
|
|
US10286058B2
(en)
|
2014-01-13 |
2019-05-14 |
Baylor Research Institute |
Vaccines against HPV and HPV-related diseases
|
|
EP3094350B1
(de)
|
2014-01-15 |
2020-03-04 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Auf knorpel gerichtete wirkstoffe und deren verwendung
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
WO2015184009A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
AU2015214264B2
(en)
|
2014-02-04 |
2018-12-20 |
Curis, Inc. |
Mutant Smoothened and methods of using the same
|
|
WO2015148915A1
(en)
|
2014-03-27 |
2015-10-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
|
WO2015175704A1
(en)
|
2014-05-14 |
2015-11-19 |
The Regents Of The University Of California |
Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria
|
|
US10005847B2
(en)
|
2014-05-27 |
2018-06-26 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
抗ｃｄ２０糖操作抗体群およびその使用
|
|
US11332523B2
(en)
|
2014-05-28 |
2022-05-17 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
|
WO2016007534A1
(en)
|
2014-07-07 |
2016-01-14 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
|
US9683017B2
(en)
|
2014-07-17 |
2017-06-20 |
University Tennessee Research Foundation |
Inhibitory peptides of viral infection
|
|
JP6811706B2
(ja)
|
2014-07-31 |
2021-01-13 |
ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー |
Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用
|
|
US10213506B2
(en)
|
2014-08-26 |
2019-02-26 |
University Of Tennessee Research Foundation |
Targeting immunotherapy for amyloidosis
|
|
US10400015B2
(en)
|
2014-09-04 |
2019-09-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant HIV-1 envelope proteins and their use
|
|
AU2015315294B2
(en)
|
2014-09-08 |
2020-09-17 |
Academia Sinica |
Human iNKT cell activation using glycolipids
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
WO2016065323A2
(en)
|
2014-10-23 |
2016-04-28 |
Singh Biotechnology, Llc |
Single domain antibodies directed against intracellular antigens
|
|
US20170267784A1
(en)
|
2014-10-23 |
2017-09-21 |
Singh Molecular Medicine, Llc |
Single domain antibodies directed against intracellular antigens
|
|
EP3875481A1
(de)
|
2014-11-14 |
2021-09-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neutralisierende antikörper gegen ebola-virus-glycoprotein und deren verwendung
|
|
CA2966964A1
(en)
|
2014-11-19 |
2016-05-26 |
Michal Novak |
Humanized tau antibodies in alzheimer's disease
|
|
WO2016090170A1
(en)
|
2014-12-05 |
2016-06-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A potent anti-influenza a neuraminidase subtype n1 antibody
|
|
US9765135B2
(en)
|
2014-12-19 |
2017-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-C5 antibodies
|
|
KR101860280B1
(ko)
|
2014-12-19 |
2018-05-21 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
|
EP3236998A1
(de)
|
2014-12-24 |
2017-11-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Rekombinante metapneumovirusproteine und deren verwendung
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
CA2972731A1
(en)
|
2015-01-24 |
2016-07-28 |
Chi-Huey Wong |
Cancer markers and methods of use thereof
|
|
EP3789766A1
(de)
|
2015-01-24 |
2021-03-10 |
Academia Sinica |
Neuartige glycankonjugate und verfahren zur verwendung davon
|
|
WO2016123591A2
(en)
|
2015-01-30 |
2016-08-04 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10330683B2
(en)
|
2015-02-04 |
2019-06-25 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
KR20170110129A
(ko)
|
2015-02-05 |
2017-10-10 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
|
EP3261665A1
(de)
|
2015-02-24 |
2018-01-03 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Mers-coronavirusimmunogene, antikörper und deren verwendung
|
|
RU2730590C2
(ru)
|
2015-02-27 |
2020-08-24 |
Чугаи Сейяку Кабусики Кайся |
Композиция для лечения заболеваний, связанных с ил-6
|
|
CN107406462B
(zh)
|
2015-03-09 |
2020-11-10 |
豪夫迈·罗氏有限公司 |
三环dlk抑制剂及其用途
|
|
CN107614062A
(zh)
|
2015-03-12 |
2018-01-19 |
加利福尼亚大学董事会 |
用RORγ抑制剂治疗癌症的方法
|
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
US10562960B2
(en)
|
2015-03-20 |
2020-02-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to gp120 and their use
|
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
|
CR20170591A
(es)
|
2015-05-22 |
2018-05-07 |
Genentech Inc |
Benzamidas sustituidas y métodos para utilizarlas
|
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
AU2016277121C1
(en)
|
2015-06-12 |
2022-07-14 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered T-cells
|
|
MA42683A
(fr)
|
2015-08-27 |
2018-07-04 |
Genentech Inc |
Composés thérapeutiques et leurs méthodes utilisation
|
|
EP3344806A4
(de)
|
2015-09-04 |
2019-03-20 |
OBI Pharma, Inc. |
Glycanarrays und verfahren zur verwendung
|
|
US11028155B2
(en)
*
|
2015-09-11 |
2021-06-08 |
Nascent Biotech, Inc. |
Enhanced delivery of drugs to the brain
|
|
EP3359570A1
(de)
|
2015-10-07 |
2018-08-15 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha-spezifische antikörper zur behandlung akuter lymphoblastischer leukämie
|
|
WO2017062820A1
(en)
|
2015-10-09 |
2017-04-13 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
|
TWI746473B
(zh)
|
2015-11-02 |
2021-11-21 |
美商辛分子醫藥有限公司 |
針對細胞內抗原之單域抗體
|
|
EP4011911A1
(de)
|
2015-11-03 |
2022-06-15 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Neutralisierende antikörper gegen hiv-1 gp41 und deren verwendung
|
|
JP2018535234A
(ja)
|
2015-11-25 |
2018-11-29 |
ジェネンテック， インコーポレイテッド |
ナトリウムチャネル遮断薬として有用な置換ベンズアミド
|
|
EP3394098A4
(de)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin-antikörper und verfahren zur verwendung
|
|
WO2017115773A1
(ja)
|
2015-12-28 |
2017-07-06 |
中外製薬株式会社 |
Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
|
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
|
US10336784B2
(en)
|
2016-03-08 |
2019-07-02 |
Academia Sinica |
Methods for modular synthesis of N-glycans and arrays thereof
|
|
SG10202007025PA
(en)
|
2016-03-14 |
2020-08-28 |
Chugai Pharmaceutical Co Ltd |
Cell injury inducing therapeutic drug for use in cancer therapy
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
TWI780045B
(zh)
|
2016-03-29 |
2022-10-11 |
台灣浩鼎生技股份有限公司 |
抗體、醫藥組合物及方法
|
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
EP3854782A1
(de)
|
2016-03-30 |
2021-07-28 |
Genentech, Inc. |
Substituierte benzamide und verfahren zur verwendung davon
|
|
KR20180128496A
(ko)
|
2016-04-22 |
2018-12-03 |
오비아이 파머 인코퍼레이티드 |
글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
|
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
|
EP3454895B1
(de)
|
2016-05-10 |
2024-03-27 |
Najit Technologies, Inc. |
Anorganische polyatomare oxyanionen zum schutz gegen antigene beschädigung während der pathogeninaktivierung zur impfstoffherstellung
|
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
|
EP3487849A1
(de)
|
2016-07-20 |
2019-05-29 |
H. Hoffnabb-La Roche Ag |
Sulfonylcycloalkylcarboxamidverbindungen als trpa1-modulatoren
|
|
JP7043483B2
(ja)
|
2016-07-20 |
2022-03-29 |
エフ．ホフマン－ラ ロシュ アーゲー |
二環式プロリン化合物
|
|
AU2017302038B2
(en)
|
2016-07-27 |
2024-03-21 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
|
TWI786054B
(zh)
|
2016-07-29 |
2022-12-11 |
台灣浩鼎生技股份有限公司 |
人類抗體、醫藥組合物、及其方法
|
|
CA3031559A1
(en)
|
2016-08-02 |
2018-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
|
WO2018025982A1
(ja)
|
2016-08-05 |
2018-02-08 |
中外製薬株式会社 |
Ｉｌ－８関連疾患の治療用又は予防用組成物
|
|
WO2018029288A1
(en)
|
2016-08-12 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Sulfonyl pyridyl trp inhibitors
|
|
KR102588027B1
(ko)
|
2016-08-22 |
2023-10-12 |
초 파마 인크. |
항체, 결합 단편 및 사용 방법
|
|
AU2017321894A1
(en)
|
2016-09-02 |
2019-03-14 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duoCARs
|
|
US10702589B2
(en)
|
2016-10-04 |
2020-07-07 |
Ann And Robert H. Lurie Children's Hospital Of Chicago |
Compositions and methods of treating neurological disorder and stress-induced conditions
|
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
|
WO2018073193A1
(en)
|
2016-10-17 |
2018-04-26 |
F. Hoffmann-La Roche Ag |
Bicyclic pyridone lactams and methods of use thereof
|
|
CN110290800A
(zh)
|
2016-11-21 |
2019-09-27 |
台湾浩鼎生技股份有限公司 |
缀合生物分子、医药组合物及方法
|
|
CN110225911B
(zh)
|
2016-11-28 |
2022-04-05 |
豪夫迈·罗氏有限公司 |
噁二唑酮瞬时受体电位通道抑制剂
|
|
WO2018100070A1
(en)
|
2016-12-02 |
2018-06-07 |
F. Hoffmann-La Roche Ag |
Bicyclic amide compounds and methods of use thereof
|
|
US11084850B2
(en)
|
2016-12-16 |
2021-08-10 |
The Pirbright Institute |
Recombinant prefusion RSV F proteins and uses thereof
|
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
|
CA3045902A1
(en)
|
2016-12-21 |
2018-06-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
|
CN110603265B
(zh)
|
2017-01-09 |
2024-01-30 |
莱蒂恩技术公司 |
用于用抗间皮素免疫治疗癌症的组合物和方法
|
|
US11021535B2
(en)
|
2017-02-10 |
2021-06-01 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
CN114874209A
(zh)
|
2017-03-07 |
2022-08-09 |
豪夫迈·罗氏有限公司 |
噁二唑瞬时受体电位通道抑制剂
|
|
JP7137896B2
(ja)
|
2017-03-24 |
2022-09-15 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ３３免疫療法によりがんを処置するための組成物および方法
|
|
CN110546148A
(zh)
|
2017-03-24 |
2019-12-06 |
基因泰克公司 |
作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
|
|
CN110678169A
(zh)
|
2017-03-31 |
2020-01-10 |
西雅图遗传学公司 |
Chk1-抑制剂与weel-抑制剂的组合
|
|
EA201992573A1
(ru)
|
2017-04-28 |
2020-04-06 |
Сиэтл Дженетикс, Инк. |
Лечение her2-положительных злокачественных новообразований
|
|
EP3620531A4
(de)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
|
|
EP3625256A1
(de)
|
2017-05-19 |
2020-03-25 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Humaner monoklonaler antikörper gegen tnfr2 zur krebsimmuntherapie
|
|
CA3066953A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Human monoclonal antibodies specific for cd33 and methods of their use
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
SG11202000333UA
(en)
|
2017-07-14 |
2020-02-27 |
Hoffmann La Roche |
Bicyclic ketone compounds and methods of use thereof
|
|
US10442867B2
(en)
|
2017-07-31 |
2019-10-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
|
|
GB201712952D0
(en)
|
2017-08-11 |
2017-09-27 |
Univ Edinburgh |
Immunomodulatory agent
|
|
EP4279086A3
(de)
|
2017-09-15 |
2024-02-28 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd19-immuntherapie
|
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
|
MA50356A
(fr)
|
2017-10-11 |
2021-04-21 |
Hoffmann La Roche |
Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1
|
|
WO2019079249A1
(en)
|
2017-10-16 |
2019-04-25 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY
|
|
EP3704097B1
(de)
|
2017-10-31 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Bicyclische sulfone und sulfoxide und verfahren zur verwendung davon
|
|
EP3703745B1
(de)
|
2017-11-04 |
2024-04-10 |
Nevada Research & Innovation Corporation |
Immunogene konjugate und verfahren zur verwendung davon
|
|
MX2020005564A
(es)
|
2017-11-30 |
2020-11-06 |
Hanmi Pharm Ind Co Ltd |
Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas.
|
|
JP7377802B2
(ja)
|
2017-12-20 |
2023-11-10 |
レンティジェン・テクノロジー・インコーポレイテッド |
免疫療法を用いてｈｉｖ／ａｉｄｓを処置するための組成物および方法
|
|
WO2019136029A1
(en)
|
2018-01-02 |
2019-07-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
TW202000201A
(zh)
|
2018-02-20 |
2020-01-01 |
瑞士商赫孚孟拉羅股份公司 |
製備1-芳基磺醯基-吡咯啶-2-甲醯胺瞬時受體電位通道拮抗劑化合物及其結晶型式之方法
|
|
WO2019165122A1
(en)
|
2018-02-21 |
2019-08-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
CN112041313A
(zh)
|
2018-02-26 |
2020-12-04 |
基因泰克公司 |
吡啶-磺酰胺化合物及其针对疼痛和相关疾患的用途
|
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
|
EP3774801A1
(de)
|
2018-03-30 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Hydro-pyrido-verbindungen mit kondensierten ringen als natriumkanalinhibitoren
|
|
JP7398391B2
(ja)
|
2018-04-20 |
2023-12-14 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物
|
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
WO2019236590A1
(en)
|
2018-06-04 |
2019-12-12 |
University Of Maryland, Baltimore |
Methods for preventing acute kidney injury
|
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
|
AU2019301675A1
(en)
|
2018-07-12 |
2021-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured CD22-specific monoclonal antibody and uses thereof
|
|
WO2020012021A1
(en)
|
2018-07-13 |
2020-01-16 |
Varct Diagnostics Aps |
Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa
|
|
US20210292428A1
(en)
|
2018-08-08 |
2021-09-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
|
EP3847154A1
(de)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamid- und sulfonamidderivate zur verwendung als tead-modulatoren
|
|
JP2022501043A
(ja)
|
2018-09-20 |
2022-01-06 |
レンティジェン・テクノロジー・インコーポレイテッドLentigen Technology, Inc. |
抗ｃｄ１２３免疫療法によりがんを処置するための組成物および方法
|
|
CA3114349A1
(en)
|
2018-09-26 |
2020-04-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
|
EP3886895A1
(de)
|
2018-11-30 |
2021-10-06 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd38-immuntherapie
|
|
US20220031830A1
(en)
|
2018-12-04 |
2022-02-03 |
The Rockefeller University |
Hiv vaccine immunogens
|
|
US20220089694A1
(en)
|
2018-12-20 |
2022-03-24 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
|
WO2020146182A1
(en)
|
2019-01-08 |
2020-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
CN113302193A
(zh)
|
2019-01-11 |
2021-08-24 |
豪夫迈·罗氏有限公司 |
双环吡咯并三唑酮化合物及其使用方法
|
|
EP3883971A1
(de)
|
2019-01-22 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Hochaffine monoklonale antikörper gegen glypican-1 und verfahren zur verwendung
|
|
TW202042820A
(zh)
|
2019-01-28 |
2020-12-01 |
美商西雅圖遺傳學股份有限公司 |
以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法
|
|
CN113924103A
(zh)
|
2019-03-06 |
2022-01-11 |
莱蒂恩技术公司 |
用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法
|
|
CN114364801A
(zh)
|
2019-05-30 |
2022-04-15 |
莱蒂恩技术公司 |
用于用抗bcma免疫治疗来治疗癌症的组合物和方法
|
|
JP2022539589A
(ja)
|
2019-07-02 |
2022-09-12 |
ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
ＥＧＦＲｖＩＩＩと結合するモノクローナル抗体およびその使用
|
|
AU2020370058A1
(en)
|
2019-10-21 |
2022-04-14 |
Seagen Inc. |
Methods of treating HER2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
|
|
CA3156761A1
(en)
|
2019-10-22 |
2021-04-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
|
MX2022005775A
(es)
|
2019-11-13 |
2022-06-09 |
Genentech Inc |
Compuestos terapeuticos y metodos de uso.
|
|
MX2022005903A
(es)
|
2019-11-15 |
2022-12-13 |
Seagen Inc |
Métodos para tratar el cáncer de mama her2 positivo con tucatinib en combinación con un conjugado fármaco-anticuerpo anti-her2.
|
|
WO2021110995A1
(en)
|
2019-12-04 |
2021-06-10 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
|
US20230032465A1
(en)
|
2019-12-12 |
2023-02-02 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates specific for cd276 and uses thereof
|
|
US20230057461A1
(en)
|
2020-01-27 |
2023-02-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
|
US20230348568A1
(en)
|
2020-02-20 |
2023-11-02 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Epstein-barr virus monoclonal antibodies and uses thereof
|
|
IL296227A
(en)
|
2020-03-11 |
2022-11-01 |
Seagen Inc |
Methods for treating her2 mutant cancer with toctinib
|
|
AU2021296423A1
(en)
|
2020-06-22 |
2023-02-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
TW202221026A
(zh)
|
2020-08-14 |
2022-06-01 |
瑞士商Ａｃ 免疫有限公司 |
人源化抗ｔｄｐ－４３結合分子及其用途
|
|
IL301405A
(en)
|
2020-09-28 |
2023-05-01 |
Seagen Inc |
Methods for treating solid tumors driven by HER2 alterations with toctinib in combination with an anti-HER2 antibody
|
|
AU2021353532A1
(en)
|
2020-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Process for the preparation of biheteroaryl compounds and crystal forms thereof
|
|
EP4229082A1
(de)
|
2020-10-16 |
2023-08-23 |
AC Immune SA |
Alpha-synuclein bindende antikörper zur therapie und diagnose
|
|
US20230391852A1
(en)
|
2020-10-26 |
2023-12-07 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
WO2022099026A1
(en)
|
2020-11-05 |
2022-05-12 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
|
EP4247849A2
(de)
|
2020-11-17 |
2023-09-27 |
Seagen Inc. |
Verfahren zur behandlung von krebs mit einer kombination aus tucatinib und einem anti-pd-1/anti-pd-l1-antikörper
|
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
KR20230146032A
(ko)
|
2021-02-15 |
2023-10-18 |
다케다 야쿠힌 고교 가부시키가이샤 |
Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
|
|
JP2024512305A
(ja)
|
2021-03-03 |
2024-03-19 |
ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
破骨細胞生成の新規制御因子としてのＬａタンパク質
|
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
CA3216228A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
WO2023281097A1
(en)
|
2021-07-09 |
2023-01-12 |
Immunic Ag |
Methods for treating cancer
|
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
|
WO2023076881A1
(en)
|
2021-10-26 |
2023-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
|
US11492394B1
(en)
|
2021-10-29 |
2022-11-08 |
Nascent Biotech, Inc. |
Kits and containers for treating vimentin expressing tumors
|
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
|
TW202342519A
(zh)
|
2022-02-16 |
2023-11-01 |
瑞士商Ａｃ 免疫有限公司 |
人源化抗ｔｄｐ－４３結合分子及其用途
|
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
|
WO2023192827A1
(en)
|
2022-03-26 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to hiv-1 env and their use
|
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
|
WO2023201333A1
(en)
|
2022-04-14 |
2023-10-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to ebola virus glycoprotein and their use
|
|
WO2023230429A1
(en)
|
2022-05-22 |
2023-11-30 |
Seagen Inc. |
Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody
|
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
|
WO2024044743A1
(en)
|
2022-08-26 |
2024-02-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
|
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|